The purpose of this study in to analyse the way in which the body processes Niagen (nicotinamide riboside) in healthy people. Blood and urine samples from subjects who are given a dose of Niagen will be analyzed for metabolites over the 24 hours after taking the dose.

Inclusion Criteria:

• Healthy Male or female age 30-55 years
• BMI 18.5-29.9 kg/m2
• If female, subject is not of child bearing potential, OR Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
• Healthy as determined by laboratory results and medical history
• Agrees to maintain current level of physical activity throughout the study
• Agrees to avoid vitamins and St. John's Wort for 30 days prior to enrollment and during the study
• Agrees to avoid nutritional yeast, whey proteins, energy drinks, dairy products, grapefruit and grapefruit juice and alcohol 7 days prior to enrollment and during study
• Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

• Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial.
• Use of natural health products (NHPs)/dietary supplements within 7 days prior to randomization and during the course of the study.
• Use of vitamins or St. John's Wort in the last 30 days before the study enrollment,
• Use of natural health products containing Nicotinamide riboside within 7 days prior to randomization and during the course of the study
• Use of nutritional yeast, whey proteins, energy drinks, grapefruit and grapefruit juice, dairy products, alcohol for 7 days prior to the study
• Subjects who are smokers
• Subjects with blood pressure ≥140/90
• Use of blood pressure medications
• Use of cholesterol lowering medications
• Metabolic diseases or chronic diseases
• Use of acute over the counter medication within 72 hours of test product dosing
• Unstable medical conditions as determined by the Qualified Investigator
• Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
• Clinically significant abnormal lab results at screening (e.g. AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN) will be assessed by the Medical Investigator
• Subjects who have planned surgery during the course of the trial
• History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable
• History of blood/bleeding disorders
• Blood donation in the past 2 months
• Alcohol abuse (>2 standard alcoholic drinks per day) or drug abuse within the past 6 months
• Participation in a clinical research trial within 30 days prior to randomization
• Allergy or sensitivity to study supplement ingredients or to any food or beverage provided during the study
• Individuals who are cognitively impaired and/or who are unable to give informed consent.
• Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject